Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification and targeting of novel CDK9 complexes in acute myeloid leukemia

26 Dec 2018

Abstract excerpt

Aberrant activation of mTOR signaling in acute myeloid leukemia (AML) results in a survival advantage that promotes the malignant phenotype. To improve our understanding of factors that contribute to mammalian target of rapamycin (mTOR) signaling activation and identify novel therapeutic targets, we searched for unique interactors of mTOR complexes through proteomics analyses. We identify cyclin dependent kinase...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Multiple Myeloma Research and Treatments
Share to PI3K/AKT/mTOR signaling in cancer
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30587525
DOI: 10.1182/blood-2018-08-870089

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification and targeting of novel CDK9 complexes in acute myeloid leukemiaPMID 30587525Read ↗

A kinase-independent role for CDK8 in BCR-ABL1+ leukemiaSemantic proximity Read ↗

Targeting mTOR in Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

Integrated Multi-Omics and Interactome Analysis of CDK8 Inhibition Reveals Erythroid Differentiation Programs and BET Synergy in AML Stem-like CellsSemantic proximity Read ↗

CDK9 inhibitors in acute myeloid leukemiaSemantic proximity Read ↗

Imaging dynamic mTORC1 pathway activity in vivo reveals marked shifts that support time-specific inhibitor therapy in AMLSemantic proximity Read ↗

Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells.Semantic proximity Read ↗

Dual targeting of MTOR as a novel therapeutic approach for high-risk B-cell acute lymphoblastic leukemiaSemantic proximity Read ↗

Targeting mTOR signaling pathways in multiple myeloma: biology and implication for therapySemantic proximity Read ↗

Conditional knockin of Dnmt3a R878H initiates acute myeloid leukemia with mTOR pathway involvement.Semantic proximity Read ↗

Targeting the mTOR Pathway in LeukemiaSemantic proximity Read ↗

The NLRP3/eIF2 axis drives cell cycle progression in acute myeloid leukemiaSemantic proximity Read ↗

ETV7 is an essential component of a rapamycin-insensitive mTOR complex in cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.